Heron Therapeutics (NASDAQ: HRTX) has recently received a number of price target changes and ratings updates: 5/2/2016 – Heron Therapeutics is now covered by analysts at Cantor Fitzgerald. They set a “buy” rating and a $41.00 price target on the stock. 4/28/2016 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group. […]
